BioSpace News Archive

Wilmington, Delaware, United States, Transparency Market Research Inc.: Cardiac rhythm management includes implantable devices which help treat and manage arrhythmia-related diseases such as cardiac arrhythmia, bradycardia, tachycardia, and cardiac synchronization

Wilmington, Delaware, United States, Transparency Market Research Inc.: Cell line development is an important technology in life sciences.

Wilmington, Delaware, United States, Transparency Market Research Inc.: The global animal parasiticides market was valued at US$ 5,606.8 Mn in 2017 and is projected to expand at a cumulative annual growth rate of 5.5% from 2018 to 2026 according to a new report published by Transparency Market Research titled “Animal Parasiticides Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

Evotec SE announced that the strategic transaction to acquire Rigenerand Srl, signed in May 2022, has been completed.

Mogrify Limited and Astellas Pharma Inc. announced that they have executed a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss.

Anebulo Pharmaceuticals, Inc. today announced positive topline data from Part A of an ongoing Phase 2 clinical trial evaluating the potential of ANEB-001 to treat ACI.

Immunovia AB announced, that Immunovia, Inc., its American subsidiary, has recently received approval for a Current Procedural Terminology Proprietary Laboratory Analyses code from the American Medical Association for the IMMray™ PanCan-d test.

KalVista Pharmaceuticals, Inc. has presented data for its oral on demand plasma kallikrein (PKa) inhibitor and Factor XIIa (FXIIa) programs at the EAACI2022 conference in Prague, Czech Republic.

Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced it will be presenting at Microbiome Connect Europe taking place between July 6-7 , 2022, in Amsterdam, Netherlands.

Lyra Therapeutics, Inc today announced that Richard Nieman, MD, has been appointed Chief Medical Officer, effective July 11, 2022.